短程同步放疗联合替莫唑胺对胶质母细胞瘤患者生存情况的影响

Influence of short term concurrent chemoradiotherapy combined with Temozolomide on the survival situations of patients with glioblastoma

目的探讨短程同步放疗联合替莫唑胺对胶质母细胞瘤患者生存情况的影响。方法选择2011年6月~2015年6月在陆军总医院附属八一脑科医院接受手术治疗的65例胶质母细胞瘤患者作为研究对象,根据治疗方案的不同分为短程同步放疗联合替莫唑胺组(联合组,23例)、短程同步放疗组(21例)和替莫唑胺组(21例)。观察三组患者近期疗效、无进展生存期(PFS)、总生存期(OS)以及不良反应发生率,并绘制三组生存曲线。结果治疗后,联合组患者客观缓解率(ORR)(56.52%)显著高于短程同步放疗组(19.05%)和替莫唑胺组(21.81%),差异有统计学意义(P<0.05),短程同步放疗组和替莫唑胺组ORR比较,差异无统计学意义(P>0.05);三组患者疾病控制率(DCR)比较,差异无统计学意义(P>0.05)。三组患者中位PFS比较,差异无统计学意义(P>0.05)。三组患者中位OS比较,差异有统计学意义(P<0.05)。三组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论 短程同步放疗联合替莫唑胺能够提高胶质母细胞瘤患者术后疾病缓解率,延长患者生存期。

Objective To investigate the influence of short term concurrent chemoradiotherapy combined with Temozolomide on the survival situations of patients with glioblastoma. Methods Sixty-five patients with glioblastoma receiving surgery treatment in the Affiliated Bayi Brain Hospital of Army General Hospital from June 2011 to June 2015 were selected as the research objects. According to the different treatments, the patients were divided into short term concurrent radiotherapy combined with Temozolomide group（combined group, 23 cases）, short term concurrent radiation group（21 cases） and Temozolomide group（21 cases）. The short term efficacy, progression free survival（PFS）, overall survival（OS） and adverse reactions of the three groups were observed. In addition, the survival curves of the three groups were drawn. Results After treatment, the objective remission rate（ORR） in the combined group（56.52%） was significantly higher than that of short term concurrent radiation group（19.05%） and Temozolomide group（21.81%）（P〉0.05）. There was no statistically significant difference of ORR between short term concurrent radiation group and Temozolomide group（P〉0.05）. There was no statistically significant difference of the disease control rate（DCR） among the three groups（P〉0.05）. There was statistically significant difference of the median PFS among the three groups（P〈0.05）.There was no statistically significant difference of the median OS among the three groups（P〉0.05）. The rate of adverse reactions among the three groups had no significant difference（P〉0.05）. Conclusion Short term concurrent radiation combined with Temozolomide can improve the postoperative remission rate of patients with glioblastoma and prolong the survival period.